{"product_id":"chemed-bcg-matrix","title":"Chemed Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eChemed’s BCG Matrix preview highlights how its core divisions—hospital services and hospice care—stack up on market share and growth, hinting at potential Stars and Cash Cows that drive cash flow and Dogs that may need pruning. This snapshot shows strategic trade-offs management faces as healthcare demand shifts. Purchase the full BCG Matrix for quadrant-level placement, data-backed recommendations, and a ready-to-use Word + Excel package to guide investment and resource-allocation decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS High-Acuity Care Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITAS High-Acuity Care Services, as Chemed’s star, dominates the fast-growing high-acuity hospice segment—VITAS held roughly 23% of US hospice admissions in 2024 while the 65+ population rose 3.1% in 2023–24, driving demand.\u003c\/p\u003e\n\u003cp\u003eThese services need heavy clinical infrastructure—ICU-level care, respiratory therapy—and command higher Medicare\/Medicaid reimbursements: hospice per-diem rates for complex care are ~25–40% above standard levels.\u003c\/p\u003e\n\u003cp\u003eChemed’s 2024 capex and staffing spend increased; VITAS expanded specialized RN and palliative teams, raising labor costs by ~8% year-over-year to protect market leadership in this niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter Water Restoration Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Roto-Rooter water restoration unit is a Star in Chemed’s BCG matrix: 10–12% CAGR market growth (IICRC\/ARC estimates to 2025) driven by climate-related losses—US flood claims rose ~30% 2015–2023—and aging pipes; it held ~15% national share in 2024 vs smaller locals. \u003c\/p\u003e\n\u003cp\u003eStrong position requires steady capex: Chemed reported ~ $35–45M annual maintenance and equipment spend for restoration in 2024, plus ongoing technician certification costs, to maintain growth and margins. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Expansion in Sunbelt Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChemed is pushing VITAS and Roto-Rooter into Sunbelt states (Florida, Texas, Arizona, North Carolina) where 65+ populations rose ~12% from 2015–2020 and single‑family housing starts increased 18% in 2024, making these territories stars due to high upfront marketing and setup costs—Chemed disclosed $120–150M annual expansion capex in 2024 tied largely to these moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Service Platform Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChemed’s investment in proprietary dispatch and patient-management tech is a Star: it boosted market share in 2024—home-health admissions up 8.4% and average response time cut 22%—while FY2024 R\u0026amp;D and implementation capex rose by ~$42m, creating a durable tech moat hard for peers to copy.\u003c\/p\u003e\n\u003cp\u003eModernizing operations is essential to keep leadership as the home-health and healthcare markets digitize; digital-driven referrals now account for ~27% of new patients, increasing lifetime revenue per patient.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8.4% admissions growth (2024)\u003c\/li\u003e\n\u003cli\u003e22% faster response time (2024)\u003c\/li\u003e\n\u003cli\u003e~$42m incremental capex (FY2024)\u003c\/li\u003e\n\u003cli\u003e27% referrals via digital channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS Community-Based Palliative Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVITAS Community-Based Palliative Care is a Star in Chemed’s BCG matrix: it targets pre-hospice serious-illness management, sits in a high-growth value-based care market (CAGR ~9–11% to 2028), and needs heavy upfront investment—Chemed disclosed ~$60–80M incremental annual CAPEX in 2024–25 to scale community programs.\u003c\/p\u003e\n\u003cp\u003eAs payer and ACO adoption rises, VITAS can capture integrated-care referrals and aims for high-margin recurring revenue; current pilot sites show 20–30% referral growth year-over-year and 15–18% EBITDA expansion potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth segment: ~9–11% CAGR\u003c\/li\u003e\n\u003cli\u003eChemed 2024–25 scale investment: ~$60–80M\u003c\/li\u003e\n\u003cli\u003ePilot referral growth: 20–30% YoY\u003c\/li\u003e\n\u003cli\u003eEstimated EBITDA upside: 15–18%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS \u0026amp; Roto-Rooter Lead Growth: Tech Boosts Admissions +8.4%, Capex Drives Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVITAS and Roto-Rooter are Stars: VITAS held ~23% hospice admissions (2024) with labor costs +8% YoY and $120–150M expansion capex; Roto-Rooter ~15% share (2024) in a 10–12% restoration CAGR to 2025 with $35–45M maintenance spend; tech capex ~$42M boosted admissions +8.4% and response time −22% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 Share\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eKey Spend\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVITAS\u003c\/td\u003e\n\u003ctd\u003e23%\u003c\/td\u003e\n\u003ctd\u003e65+ ↑3.1%\u003c\/td\u003e\n\u003ctd\u003e$120–150M exp capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoto-Rooter\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003ctd\u003e10–12% CAGR\u003c\/td\u003e\n\u003ctd\u003e$35–45M maint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTech\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003eAdmissions +8.4%\u003c\/td\u003e\n\u003ctd\u003e$42M capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Chemed’s units with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Chemed BCG Matrix placing each business unit in a quadrant for quick strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter Core Plumbing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter plumbing is a mature market leader with ~1,200 service locations and a 2024 estimated segment revenue around $1.6 billion, producing high-margin, steady cash flow and low capex relative to sales.\u003c\/p\u003e\n\u003cp\u003eIts free cash flow funded Chemed’s $32 per-share special dividend in 2024 and supported the company’s $450 million acquisition budget, making Roto-Rooter the portfolio’s financial backbone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVITAS Routine Home Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVITAS Routine Home Care delivers steady, high-market-share hospice services under Medicare, generating sustainable margins—Chemed reported hospice segment adjusted EBITDA margin ~22% in FY2024, with VITAS as the core driver.\u003c\/p\u003e\n\u003cp\u003eExisting national home-health infrastructure cuts incremental costs, yielding strong cash conversion; VITAS recorded consistent operating cash flow near $300M in 2024.\u003c\/p\u003e\n\u003cp\u003eMinimal promo spend is needed since VITAS is a preferred name in referral networks, keeping SG\u0026amp;A intensity low and supporting repeatable liquidity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter Commercial Maintenance Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter commercial maintenance contracts deliver steady recurring revenue from long-term agreements with national accounts, representing about 28% of Chemed’s 2024 Service segment revenue and showing single-digit organic growth.\u003c\/p\u003e\n\u003cp\u003eLow market growth but high margins—operating margins near 22% in 2024—reflect economies of scale and strong retention, creating a high barrier to entry.\u003c\/p\u003e\n\u003cp\u003eCash from this mature segment funds Stars and Question Marks; Chemed generated roughly $420 million free cash flow in 2024, much of which is redeployed for growth and acquisitions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Urban VITAS Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished Urban VITAS Programs in Miami and Chicago are cash cows: mature hospice operations with peak market penetration (estimated 65–75% regional share) and optimized staffing models driving EBITDA margins around 18–22% in 2024, generating steady free cash flow used to service Chemed’s corporate debt.\u003c\/p\u003e\n\u003cp\u003eThese programs leverage deep community trust and referral networks, average daily census stability (Miami ~1,200; Chicago ~950 in 2024), and low incremental capex, making them primary cash generators for corporate obligations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature markets: Miami, Chicago\u003c\/li\u003e\n\u003cli\u003eRegional share: 65–75%\u003c\/li\u003e\n\u003cli\u003eEBITDA margins: 18–22% (2024)\u003c\/li\u003e\n\u003cli\u003eAverage daily census: Miami ~1,200; Chicago ~950 (2024)\u003c\/li\u003e\n\u003cli\u003eRole: steady free cash flow for debt service\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoto-Rooter Franchise Royalty Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoto-Rooter franchise royalties deliver high-margin, low-overhead cash flow—Chemed reported franchise and licensing revenue of $218 million in 2024, largely pure profit requiring minimal capital or active management.\u003c\/p\u003e\n\u003cp\u003eThis mature revenue stream stabilizes earnings, boosts adjusted EBITDA margins (Chemed’s 2024 adjusted EBITDA margin ~21%), and raises corporate valuation by adding predictable, recurring free cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 franchise revenue: $218M\u003c\/li\u003e\n\u003cli\u003eMinimal capex and SG\u0026amp;A allocation\u003c\/li\u003e\n\u003cli\u003eHigh contribution to adjusted EBITDA (~21%)\u003c\/li\u003e\n\u003cli\u003eStable, recurring cash enhances valuation multiples\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChemed’s $420M FCF Engine: Roto-Rooter, VITAS Fuel $450M M\u0026amp;A \u0026amp; Dividends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoto-Rooter and VITAS are Chemed’s cash cows: combined 2024 free cash flow ~420M, Roto-Rooter revenue ~1.6B, franchise\/licensing 218M, hospice adjusted EBITDA ~22%, Urban VITAS programs (Miami\/Chicago) census ~1,200\/950 and EBITDA 18–22%, funding dividends, debt service, and a $450M acquisition budget.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCombined FCF\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoto-Rooter rev\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFranchise rev\u003c\/td\u003e\n\u003ctd\u003e$218M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospice adj. EBITDA\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiami\/Chicago census\u003c\/td\u003e\n\u003ctd\u003e1,200\/950\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition budget\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eChemed BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Chemed BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. This preview matches the downloadable document verbatim, crafted by strategy experts and populated with market-informed insights for immediate use. Upon purchase you’ll get the full, editable file delivered to your inbox—ready to print, present, or integrate into your planning without further changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748184076665,"sku":"chemed-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/chemed-bcg-matrix.png?v=1772205831","url":"https:\/\/growthsharematrix.com\/products\/chemed-bcg-matrix","provider":"Growth Share Matrix","version":"1.0","type":"link"}